211 related articles for article (PubMed ID: 15725809)
1. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.
Hansel DE; Dhara S; Huang RC; Ashfaq R; Deasel M; Shimada Y; Bernstein HS; Harmon J; Brock M; Forastiere A; Washington MK; Maitra A; Montgomery E
Am J Surg Pathol; 2005 Mar; 29(3):390-9. PubMed ID: 15725809
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
[TBL] [Abstract][Full Text] [Related]
3. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
4. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia.
Sagatys E; Garrett CR; Boulware D; Kelley S; Malafa M; Cheng JQ; Sebti S; Coppola D
Hum Pathol; 2007 Oct; 38(10):1526-31. PubMed ID: 17640711
[TBL] [Abstract][Full Text] [Related]
5. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
[TBL] [Abstract][Full Text] [Related]
6. Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma.
Pizzi M; Fassan M; Realdon S; Balistreri M; Battaglia G; Giacometti C; Zaninotto G; Zagonel V; De Boni M; Rugge M
Hum Pathol; 2012 Nov; 43(11):1839-44. PubMed ID: 22521076
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA expression profiles of esophageal cancer.
Feber A; Xi L; Luketich JD; Pennathur A; Landreneau RJ; Wu M; Swanson SJ; Godfrey TE; Litle VR
J Thorac Cardiovasc Surg; 2008 Feb; 135(2):255-60; discussion 260. PubMed ID: 18242245
[TBL] [Abstract][Full Text] [Related]
8. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.
Lu D; Vohra P; Chu PG; Woda B; Rock KL; Jiang Z
Am J Surg Pathol; 2009 Apr; 33(4):521-5. PubMed ID: 19047899
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Lord RV; Park JM; Wickramasinghe K; DeMeester SR; Oberg S; Salonga D; Singer J; Peters JH; Danenberg KD; Demeester TR; Danenberg PV
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):246-53. PubMed ID: 12579092
[TBL] [Abstract][Full Text] [Related]
10. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
12. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue.
Sabo E; Meitner PA; Tavares R; Corless CL; Lauwers GY; Moss SF; Resnick MB
Clin Cancer Res; 2008 Oct; 14(20):6440-8. PubMed ID: 18927283
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus.
Katada N; Hinder RA; Smyrk TC; Hirabayashi N; Perdikis G; Lund RJ; Woodward T; Klingler PJ
Arch Surg; 1997 Jul; 132(7):728-33. PubMed ID: 9230856
[TBL] [Abstract][Full Text] [Related]
14. MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions.
Choy B; LaLonde A; Que J; Wu T; Zhou Z
Hum Pathol; 2016 Nov; 57():126-135. PubMed ID: 27476776
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
16. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
[TBL] [Abstract][Full Text] [Related]
17. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
18. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
Abraham SC; Wang H; Wang KK; Wu TT
Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
Lagorce C; Paraf F; Vidaud D; Couvelard A; Wendum D; Martin A; Fléjou JF
Histopathology; 2003 May; 42(5):457-65. PubMed ID: 12713622
[TBL] [Abstract][Full Text] [Related]
20. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]